Photo by atikahakhtar from unsplash
Registry data suggest that people with immune‐mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID‐19) outcomes compared with patients receiving no systemic treatments. Click to show full abstract
Registry data suggest that people with immune‐mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID‐19) outcomes compared with patients receiving no systemic treatments.
Keywords:
behaviours people;
people inflammatory;
mitigating behaviours;
disease;
covid;
risk mitigating
Journal Title: British Journal of Dermatology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Dermatology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!